What Happened?
San Diego, CA-based Turning Point Therapeutics Appointed Paolo Tombesi as Executive Vice President and C.F.O.
About the Company
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
About the Person
Paolo Tombesi is Executive Vice President and C.F.O. at Turning Point Therapeutics. Previously, Paolo held various senior HR leadership roles in the industry.
Info Source
News
Short Profile